Call us +91 -7376325889/ 7376335889
Mail
Support
Partners
Careers
Knowledge Center
Downloads
Margin Calculator
Equity
F&O
MF
Online Trading
Open an Account
Back Office
Apply IPO
ABOUT US
SERVICES
MARKETS
Equity
Derivatives
Mutual Fund
IPO
PORTFOLIO
OUR RECOMMENDATIONS
CONTACT US
CALCULATORS
ANNUAL INCOME RANGE
BANK MODIFICATION
MENU
×
HOME
SERVICES
MARKETS
PORTFOLIO
OUR RECOMMENDATIONS
ABOUT US
SERVICES
CONTACT US
CALCULATORS
Online Trading
Open an Account
Back Office
Apply IPO
Equity Analysis
Company Profile
Price
Volume
Analysis
Company Profile
News Analysis
Corporate Action
Other Markets
Detailed Quotes
Detailed Quotes
Company Snapshot
Company Background
Board of Directors
Profit & Loss
Balance Sheet
Quarterly Results
Key Financial Ratios
Share Holding Pattern
Directors Report
Score Board
MF Holdings
Name Change
Company News
Peer Comparison
Monthly High / Low
Price Chart
Consolidated Quarters
FII Holding
Simple & CAGR Growth
Deliverable Volumes
Company News
Glaxosmithkline Pharmaceuticals Ltd
Industry : Pharmaceuticals - Multinational
BSE Code
ISIN Demat
Book Value(
)
500660
INE159A01016
98.8545682
NSE Symbol
P/E(TTM)
Mar.Cap(
Cr.)
GLAXO
50.19
42500.59
EPS(TTM)
Face Value(
)
Div & Yield %:
49.99
10
1.28
Back
Board of SBI Cards & Payment Services approves change in directorate
Feb 17,2025
The Board of SBI Cards & Payment Services at its meeting held on 17 February 2025 has approved the appointment of Salila Pantle as Managing Director & CEO (nominated by State Bank of India) (DIN: 10941529) of the Company with effect from 01 April 2025 for a period of two years. She replaces Abhijit Chakravorty who superannuated from the services of State Bank of India with effect from 31 March 2025.